French pharmaceutical giant Sanofi will invest around 1 billion euros to establish a new insulin production base in Beijing, according to the Beijing Economic-Technological Development Area (BDA).
On Monday, Sanofi signed a memorandum of cooperation with the Beijing Municipal Bureau of Economics and Informatization and the BDA Administrative Committee to build the facility in Yizhuang, in the south of the city. This will be Sanofi’s fourth production and supply base in China and represents its largest single investment in the country to date.
Sanofi Chief Executive Paul Hudson noted that the new production base with advanced automated production technologies, cutting-edge digital integrated management systems and sustainable environmental standards will further enhance the company’s supply chain resilience and efficiently serve to the growing needs of patients with diabetes.
Headquartered in Paris, Sanofi has been present in China since 1982. The company operates several production and research and development (R&D) facilities across the country.
Source: https://www.chinahoje.net/sanofi-investira-1-bilhao-de-euros-em-base-de-producao-de-insulina-em-beijing/
